Persones / Equip Humà

Susana Rives Solà

Buscador de publicacions

Publicacions

  • Marina Caballero Bellón, Alonso-Saladrigues A, Bobillo-Perez S, Faura A, Arqués L, Rivera C, Català-Temprano A, Dapena JL, Rives-Solà S and Jordán-García I.

    Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

    FRONTIERS IN IMMUNOLOGY . 14: 1219289-1219289. Nº de cites: 3

    [doi:10.3389/fimmu.2023.1219289]

  • Esperanza-Cebollada E, Gomez-Gonzalez S, Pérez-Jaume S, Vega-García N, Vicente-Garces C, Richarte M, Rives-Solà S, Català-Temprano A, Torrebadell-Burriel M and Camós-Guijosa M.

    A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia

    BRITISH JOURNAL OF HAEMATOLOGY . 202(1): 96-110. Nº de cites: 5

    [doi:10.1111/bjh.18746]

  • Vicente-Garces C, Maynou-Fernández J, Fernandez-Isern G, Esperanza-Cebollada E, Torrebadell-Burriel M, Català-Temprano A, Rives-Solà S, Camós-Guijosa M and Vega-García N.

    Fusion InPipe, an integrative pipeline for gene fusion detection from RNA-seq data in acute pediatric leukemia

    Frontiers in Molecular Biosciences . 10: 1141310-1141310. Nº de cites: 2

    [doi:10.3389/fmolb.2023.1141310]

  • Moreno C, Ramos-Elbal E, Velasco P, Aguilar Y, Gonzáález Martínez B, Fuentes C, Molinos Á, Guerra-García P, Palomo P, Verdu J, Adán Pedroso RM, Vagace JM, López-Duarte M, Regueiro A, Tasso M, Dapena JL, Salinas JA, Navarro S, Bautista F, Lassaletta Á, Lendínez F, Rives-Solà S, Pascual A, Rodríguez A, Pérez-Hurtado JM, Fernández JM, Pérez-Martínez A, González-Vicent M, Díaz de Heredia C and Fuster JL.

    Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet).

    Frontiers in pediatrics . 11: 1140637-1140637. Nº de cites: 1

    [doi:10.3389/fped.2023.1140637]

  • Laetsch TW, Maude SL, Rives-Solà S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M, Buechner J, Pulsipher MA, Myers GD, Stefanski HE, Martin PL, Nemecek E, Peters C, Yanik G, Khaw SL, Davis KL, Krueger J, Balduzzi A, Boissel N, Tiwari R, O'Donovan D and Grupp SA.

    Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

    JOURNAL OF CLINICAL ONCOLOGY . 41(9): 1664-1669. Nº de cites: 128

    [doi:10.1200/JCO.22.00642]

  • Ghorashian S, Jacoby E, De Moerloose B, Rives-Solà S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, Algeri M, Locatelli F, Vettenranta K, Gonzalez B, Attarbaschi A, Harris S, Bourquin JP and Baruchel A.

    Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study

    LANCET HAEMATOLOGY . 9(10): 766-775. Nº de cites: 25

    [doi:10.1016/S2352-3026(22)00225-3]

  • Bueno C, Barrena S, Bataller A, Ortiz-Maldonado V, Elliott N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, Gonzalez M, Morgades M, Sorigué M, Barcena P, Zanetti SR, Torrebadell-Burriel M, Vega-García N, Rives-Solà S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan-Otero M, Delgado J, Urbano-Ispizua Á, Ribera JM, Orfao A, Roy A and Menéndez P.

    CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    Blood . 140(1): 38-44. Nº de cites: 21

    [doi:10.1182/blood.2021014840]

  • Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives-Solà S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F and Zwaan CM.

    Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

    Leukemia . 36(6): 1516-1524. Nº de cites: 34

    [doi:10.1038/s41375-022-01576-3]

  • Laetsch TW, Maude SL, Balduzzi A, Rives-Solà S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R and Grupp SA.

    Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia

    Leukemia . 36(6): 1508-1515. Nº de cites: 20

    [doi:10.1038/s41375-022-01550-z]

  • Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Dapena JL, Rives-Solà S, Sevilla J, Menárguez López Á, Panesso Romero M, Montoya C, Vagace JM, Molina Hurtado JR, García-Morín M, García Abós M, Mendoza Sánchez MC, Lendínez F, Palomo Moraleda P, Tallón M, González B, Urrutia E, Serna JV, Peláez Pleguezuelos I, Martínez Merino M, Ramos Elbal E, Orellana E, Benítez Muñoz H and Berrueco R.

    Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS . 20(6): 1390-1399. Nº de cites: 8

    [doi:10.1111/jth.15699]